Division of Internal Medicine, Hematology Service, Regional Hospital "A. Cardarelli", Campobasso, Italy.
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Haematology Unit, University Hospital "P. Giaccone", University of Palermo, Via del Vespro 127, 90127, Palermo, Italy.
Ann Hematol. 2021 Sep;100(9):2173-2179. doi: 10.1007/s00277-020-04361-3. Epub 2020 Dec 2.
Iron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient's perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. In this multicentric randomized study, we analyze the cost-effectiveness of intravenous sodium ferrigluconate vs oral Sucrosomial iron in patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption.
缺铁性贫血是最常见的导致残疾的原因之一。静脉铁是纠正缺铁的最快方法，它绕过了铁肠吸收的瓶颈，这是人体铁平衡调节的唯一真正机制。对于口服硫酸亚铁不耐受/耐药的患者，建议使用静脉铁。然而，静脉铁给药需要注意一些事项；由于在医院内给药需要复苏服务，正如欧洲药品管理局所规定的，它非常昂贵，并对患者的感知生活质量产生负面影响。一种新的口服铁制剂，Sucrosomial 铁，绕过了正常的吸收途径，在纠正缺铁性贫血方面似乎具有成本效益，其剂量高于其他口服铁制剂通常有效的剂量。在这项多中心随机研究中，我们分析了静脉注射葡萄糖酸亚铁钠与口服 Sucrosomial 铁在缺铁性贫血患者中的成本效益，这些患者对口服硫酸亚铁不耐受/耐药，且无其他影响铁吸收的因素。
